Ultragenyx Pharmaceutical (RARE) Capital Leases (2019)
Ultragenyx Pharmaceutical (RARE) reported Capital Leases of $31.2 million for Q3 2019, down 5.34% on a QoQ basis from $33.0 million in Q2 2019.
Ultragenyx Pharmaceutical (RARE) has 1 years of Capital Leases data on file, last reported at $31.2 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 31.21 Mn |
| Jun 30, 2019 | 32.97 Mn |
| Mar 31, 2019 | 22.98 Mn |